Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS

PHASE3CompletedINTERVENTIONAL
Enrollment

720

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Pneumococcal Vaccines
Interventions
BIOLOGICAL

13 valent Pneumococcal Conjugate Vaccine

0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1

BIOLOGICAL

13 valent Pneumococcal Conjugate Vaccine

0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1

BIOLOGICAL

13 valent Pneumococcal Conjugate Vaccine

0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1

BIOLOGICAL

23-valent Pneumococcal Polysaccharide Vaccine

0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1

BIOLOGICAL

23-valent Pneumococcal Polysaccharide Vaccine

0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1

Trial Locations (6)

27609

Pfizer Investigational Site, Raleigh

33024

Pfizer Investigational Site, Pembroke Pines

37620

Pfizer Investigational Site, Bristol

45229

Pfizer Investigational Site, Cincinnati

83704

Pfizer Investigational Site, Boise

85224

Pfizer Investigational Site, Chandler

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00574548 - Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS | Biotech Hunter | Biotech Hunter